Board of Directors

Andrew Hull, BA

Charmain of the Board of Directors

Mr. Hull has over 30 years of experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He most recently served as Vice President of Global Alliances for Takeda Pharmaceuticals where he was responsible

for maximizing the success of Takeda’s growing number (40+) of commercial and R&D partnerships with many of the industry’s leading pharmaceutical and biotech companies. In previous roles, he led marketing and commercial development of Takeda’s United States portfolio of over $3 billion, including diabetes, neuroscience, gastrointestinal and cardiovascular therapies. Additionally, he held positions of increasing responsibility at Immunex and Abbott Laboratories.

Mr. Hull received a bachelor’s degree in biology from Kenyon College in 1985. He also recently served as a member of the Board of Directors of the Illinois Biotechnology Industry Organization and recently was a member of the Kenyon College Board of Trustees. Mr. Hull serves as a Director of Zucara Therapeutics, Inc.

Learn More

Janet Grove, QC

Director

Janet Grove is a corporate lawyer and partner at Norton Rose Fulbright Canada LLP where she is Canadian head of their Life Sciences and Healthcare Group.Janet was previously managing partner of Vancouver based law firm, Bull, Housser & Tupper LLP and led Bull, Housser in its merger discussions with global law firm, Norton Rose Fulbright.

She then served as managing partner of Norton Rose Fulbright’s Vancouver office until her term expired at the end of 2019. She was named one of Canada's Top 100 Most Powerful Women in 2017 by Women’s Executive Network and appointed Queen’s Counsel in 2020. Ms. Grove also currently serves on the board of Genome BC and sits on the Audit and Assurance Council of Canada. She is also a former Chair and director of St. John Ambulance Vancouver Branch and a former director of Canadian Business for Social Responsibility. In 2000, Janet joined the legal team at a Canadian biotechnology company then listed on the TSX and NASDAQ, where she was a member of the company’s executive management team. She held a number of roles, including the position of Vice-President and Corporate Counsel, Corporate Secretary, and Business Ethics Officer prior to returning to private practice in 2008.

Learn More

Bryan Baldasare

Director

Mr. Baldasare is a well-rounded biotech executive with wealth of experience in finance and accounting, financial planning and analysis, treasury management, commercial operations and mergers and acquisitions.

Mr. Baldasare spent over 20 years at Meridian Bioscience, most recently as Chief Financial Officer where during his tenure, grew its revenues by over 500%, developed and launched dozens of new products, expanded into a diversified global business with 15 sites in 10 countries. Mr. Baldasare is currently the CFO at Hilltop Companies, a leading supplier to the construction industry. Prior to Meridian, Mr. Baldasare spent over 10 years in public accounting at Arthur Andersen LLP.

Mr. Baldasare has a Bachelor’s degree in Business Administration from the University of Cincinnati.

Learn More

Nicole Lemerond, CFA

Director

Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance.

She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public and private company management teams and boards to increase stakeholder value. She established and led healthcare groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group.

Ms. Lemerond holds a Bachelor of Science degree from Cornell University and is a CFA charterholder.

Learn More

Eric A. Adams, MIBS

Chief Executive Officer & President

Mr. Adams is a seasoned biopharmaceutical executive with more than 30 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance.

Mr. Adams has been our President and Chief Executive Officer, and a Director, since 2016. He previously served as CEO at enGene Inc. Prior to enGene, he held senior roles in global market development with QLT Inc., Advanced Tissue Sciences Inc., Abbott Laboratories, and Fresenius AG (Germany).

He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Learn More

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.

Learn More

Management

Learn More

Scientific Advisory Board

Learn More